Proliferative VitreoretinopathyNCT07682025
Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.
An observational study of Proliferative Vitreoretinopathy, run by University College, London at 1 site in United Kingdom.
Trial summary
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR). Study aims to help tailor patients' treatments and improve outcomes by: [i] studying imaging biomarkers of PVR, and [ii] develop AI models for… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Proliferative Vitreoretinopathy
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 12 Oct 2026to 15 Oct 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MORPH-1 - PVR detachments Cohort-NHS - primary RRD without PVR requiring PPV with PVD.
Who may be able to join
- MORPH-1 and Cohort-NHS study imaging
Who cannot join
- Participants from above studies who have not consented for image analysis and AI related analysis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Identification of Imaging Biomarkers and Predictive Modelling of Proliferative Vitreoretinopathy Using Deep Learning.
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).
Study aims to help tailor patients' treatments and improve outcomes by:
Read more
[i] studying imaging biomarkers of PVR, and [ii] develop AI models for PVR detection.
Inclusion:
- Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1.
- Patients with 'simple' retinal detachment without PVR recruited to a PhD study.
Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.
- Conditions
- Proliferative Vitreoretinopathy
- Medical subject headings
- Vitreoretinopathy, Proliferative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Rhegmatogenous retinal detachment without proliferative vitreoretinopathy | Rhegmatogenous retinal detachment without proliferative vitreoretinopathy at the time of their primary surgery | |
| Rhegmatogenous retinal detachment with proliferative vitreoretinopathy | Rhegmatogenous retinal detachment with proliferative vitreoretinopathy at the time of their primary surgery or post-operatively with recurrent retinal detachment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To study multimodal imaging biomarkers of PVR.
Use multimodal imaging namely widefield Optos, Widefield OCT, OCT macula, OCT disc, OCT EDI and OCTA to describe biomarkers of PVR.
Measured: Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.
Secondary outcomes (1)
To develop deep learning AI models for PVR detection in retinal detachment.
Use widefield Optos imaging and OCT to:
- Develop outputs for presence of PVR (binary), and
- Develop output for prediction of PVR grade.
Measured: Post-operative 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2026
- Study start12 Oct 2026 (estimated)
- Primary completion15 Oct 2027 (estimated)
- Study completion15 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Proliferative VitreoretinopathyStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- James Bainbridge, Principal investigator, University College, London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07682025
- Sponsor's protocol ID
- EDGE 183954
- Status last verified
- Jun 2026
- First submitted
- 5 May 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Within participant's consent.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Imaging Biomarkers and Predictive Modelling of Proliferative Vitreoretinopathy Using Deep Learning.
- ClinicalTrials.gov ID
- NCT07682025
- Acronym / sponsor ID
- EDGE 183954
- Conditions
- Proliferative Vitreoretinopathy
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Study start
- 12 Oct 2026 (estimated)
- Primary completion
- 15 Oct 2027 (estimated)
- Study completion
- 15 Oct 2027 (estimated)
- First posted
- 2 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).
Study aims to help tailor patients' treatments and improve outcomes by:
[i] studying imaging biomarkers of PVR, and [ii] develop AI models for PVR detection.
Inclusion:
- Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1.
- Patients with 'simple' retinal detachment without PVR recruited to a PhD study.
Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rhegmatogenous retinal detachment without proliferative vitreoretinopathy | – | –Rhegmatogenous retinal detachment without proliferative vitreoretinopathy at the time of their primary surgery |
| Rhegmatogenous retinal detachment with proliferative vitreoretinopathy | – | –Rhegmatogenous retinal detachment with proliferative vitreoretinopathy at the time of their primary surgery or post-operatively with recurrent retinal detachment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MORPH-1 - PVR detachments Cohort-NHS - primary RRD without PVR requiring PPV with PVD.
Key inclusion criteria (1 listed)
- MORPH-1 and Cohort-NHS study imaging
Key exclusion criteria (1 listed)
- Participants from above studies who have not consented for image analysis and AI related analysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To study multimodal imaging biomarkers of PVR.
Time frame: Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.
Use multimodal imaging namely widefield Optos, Widefield OCT, OCT macula, OCT disc, OCT EDI and OCTA to describe biomarkers of PVR.
1 secondary outcome
To develop deep learning AI models for PVR detection in retinal detachment.
Time frame: Post-operative 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No. Within participant's consent.
Related trials for Proliferative Vitreoretinopathy
RecruitingPhase 2
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
Participants With Underactive Bladder (UAB)
RecruitingPhase 2
Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Not yet recruitingPhase 1
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy
RecruitingPhase 1/2
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Active, not recruiting
Comparison of Visual Outcomes of Pars Plana Vitrectomy With and Without Injection Clexane for Rhegmatogenous Retinal Detachment Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment With Grade C Proliferative Vitreoretinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
James Bainbridge principal investigator
University College, London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Proliferative Vitreoretinopathy, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To study multimodal imaging biomarkers of PVR. (time frame: Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.